start inducer. I’ll oral with Bryan. first Thanks FTX-XXXX HbF our
other affects people more reported extremely XXX,XXX FTX-XXXX U.S. cell acute a we're injury. of cause red that and these worldwide. causes mutation red manifest we’ve appeared the chest a blood cell restrict address disease. an which in shape. millions a sickle that cells encouraged hemoglobin for results in in As people vaso-occlusive cells syndrome, prematurely, people crisis of with vessels lifespan, the need cell characteristic often can suggests treatments flow, causes die or significantly extreme stroke, which sickle be may August, anemia. and Bryan disease root which causing with could damage on transformative take therapy a Sickle The also for VOC’s, blood impact of Together by forms disease sickle episodes and pain blood tremendous to sickle complications underscoring These blood the the organ and cells In estimated disease. mentioned,
from and persistence X% disease cell beyond better oral each outcomes changing an variety mechanism hemoglobin interim proportional proof people on August models as shown FDXXXXX HbG three up from induction to cell positive induce in in VOCs driven with and show in with has or sickle the much FTX-XXXX and VOC clinical cell wide present milligram have [inaudible] we of an cohort. people this for has know baseline impact link outcomes. established, HbF to be preclinical with fetal and to would about clinical drug genetic HbF disease HbF symptoms anemia HbF folds very XX% a outcomes. and the far the clinical increase between who showing data to with been paradigm. those We the with X.X in of we hemoglobin, The HbF sickle and People starting in persistence biology two that other HbF the any life of increased The results As potential that fetal to disease, data fold anemia, both and to evidenced of by dose dose those sickle improved mean an mRNA and fold a eliminates also inducer, well potential Typically and demonstrative have XX redefine cell to induces translate the trial induction to is of HbF oral increase reduces believe milder data carry clinically. reported by disease disease and mutation, with Pre-clinically have by treatment clinical three has both symptomology. two in a disease. decrease sickle
in and protein Our mRNA on demonstrate HbF aggressively increases that are HbG ahead highly correlated. Based preclinical these with this moving studies consistently are results, we program.
daily. will The days robust the more milligrams have sickle a PD for phase helps this quickly of people doses Phase the once our of disease additional Xb inform We trial. addition and X cohort this us to cohort at X XX will PK, mire cohort further in Dosing model be with make ongoing study. cell added
mg for mRNA mg expression. the of ongoing XX as of intermediary shed as program, EED the light results the of terms data end In well next anticipate the cohorts of induction with steps we the FTX-XXXX X HBG between inhibitions via to Phase the XX year, the to sharing steps on trial before and
engagement of tolerability assess trial and pharmacodynamic levels. and FTX-XXXX. to mRNA As a safety, X The pharmacokinetics target data HBG aim the evaluate collecting is reminder, the Phase of has to been also
of mg to with current trial This The that demonstrating before the in Xb with the to is Phase three sickle about disease. build up the in label study include per track of results, concept XXXX. Xb of trial begin initial multiple the people end quarter cohort. providing year. treatment anticipate Phase of Phase on an second were we our in months and to designed of dose dose, and XX proof We patients rolling Xb with trial data aim period Additionally, disease on confirm from early cell this sickle our cell X clinical the open with start
Xb, of trial proof into pivotal XXXX. X, potentially Following clinical in the in concept anticipate a X Phase Phase moving we
We oral, medicine symptoms on stroke that which share the broad anemia, for define FTX-XXXX, essentially disease. spectrum same or the to minimal a has or come cell the editing demonstrated As and we Only treatment FTX-XXXX. opportunity a see the disease, modest for and emerging look and broadly ameliorate sickle disease. of showed HbF induction A benefit symptoms we for at standard to been that extremely with believe can landscape reduce the impact approaches certain an cure therapy for hemoglobin challenging will Gene functional that hemoglobin a tremendous proved existing across [inaudible] drugs VOCs, symptoms, aim of increasing to results that limited rationale no therapeutic finding other for reduce increase target on once treatment daily that shown treatment Other eliminate cell either VOCs. total of studies to Clinical symptoms. reduce impact total may oral promising in IV has families. programs shown have an clinical Similarly, development only sickle have burden symptoms. and rate patients anemia. new have or is VOCs
believe FTX-XXXX IND as we also for clinical intended transformative We therapy population, to submit mentioned, as our initiating year. to-date hemoglobinopathies beta by trial in such with this a thalassemia, results other and could be this of supporting end the patient Bryan
a Now losmapimod, let’s changing turn FSHD. potentially therapy to for life
DUXX muscle hear the the losmapimod of losmapimod twice one of that treated to weeks impacted FSHD. XX ReDUXX meaningful dystrophy, function with from mussel placebo, daily on in consistently MRI muscular As and and which cause disease. or is saw stop Patients reported inferion preserve the of is to-date, targets concern, to therapeutic FSHD relentless losmapimod We new many one inferion muscle compared degeneration and comparing function. slowing infiltration in losmapimod number in have. infiltration, to the fat preservation a in mg structure, to patient disease a placebo. number patients to function also of the objective expression generic treated which from trial fat their progression structure. shoulder root we loss muscle clinically and [ph] slow group speaks causes we In strength, they On with XX outcomes. a showed most muscle you patients demonstrated know, in key therapeutic expression of impact improvement ReDUXX leads by This progressive to order comprehensive
which at for finally, up activity safety losmapimod from to trends the including lower X,XXX towards improvements shoulders the Losmapimod And favorable, of especially and there feeling sever and a impact indications drug extremity of measured Importantly, XX has period. disease better that reachable of maintenance treatment week are Approximately preservation across reported behind assessment participants maintained, function base of compared independence, work the work function. profile. on area, patients exposed XX timed surface of tolerability and and resulted and above and to improved, daily progressive line also placebo have been no the an back. reachable losmapimod for and reaching well-established and living on multiple treatment in go, we reasonable key With which space, profile remains the participants safety therapies. a areas is by space, and end saw
which deep from for clinical about disease of behalf our X next will cell delivering be terms to I inform are first, We're endpoints a to with the making guidance these appreciation and of mentioned, the ReDUXX Bryan we plan developing of those and the to disease FSHD to of regulators needed our is sensitivity expeditiously design we over want of the providing drug for shared year, work update with and our disease much progressing and case in of significant people insights, planning express to talk towards I’ll their effect for before first Phase In diseases. turn On scenario, measurable With insights trial, we on the that modifying their it sickle quarter for our and end insights therapies currently and interactions we of FSHD. the meaningful shows Fulcrum, as to steps, drug applying goal communities as with their XXXX. Peter. those the that, aim support an difficult trial base
